Informing patients about potential adverse drug reactions after percutaneous coronary intervention reduces the occurrence of self-reported adverse drug reactions
Pettersen T, Schjott J, Allore H, Bendz B, Borregaard B, Fridlund B, Hadjistavropoulos H, Larsen A, Nordrehaug J, Rasmussen T, Rotevatn S, Valaker I, Wentzel-Larsen T, Norekval T. Informing patients about potential adverse drug reactions after percutaneous coronary intervention reduces the occurrence of self-reported adverse drug reactions. European Heart Journal 2022, 43: ehac544.2736. DOI: 10.1093/eurheartj/ehac544.2736.Peer-Reviewed Original ResearchSelf-reported adverse drug reactionsPercutaneous coronary interventionAdverse drug reactionsPotential adverse drug reactionsHospital dischargePrescribed therapyDrug reactionsCoronary interventionMedical recordsOdds ratioIncidence of ADRsProspective multicentre cohort studyStable coronary artery diseaseMulticentre cohort studyCoronary artery diseaseConfidence intervalsPatients' medical recordsHeart ContinuityInforming PatientsMore comorbiditiesIndex hospitalizationCohort studyArtery diseasePCI centerClinical variables